Scientists at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts have demonstrated non-viral gene therapy that may delay degenerative eye disorders. The research was conducted in a study to be published in Molecular Therapy.
The gene therapy relies on nanoparticles to protect DNA and prevent retinal cell death, according to Rajendra Kumar-Singh, senior author of the study and associate professor of ophthalmology at the school of medicine. Kumar-Singh also noted that, rather than use nanoparticles, gene therapy typically relies on a virus for DNA delivery, even though the immune response could lead to inflammation, cancer or death.
The research team conducted a gene therapy test on mice, which showed better eyesight seven days after the subjects receiveg treatment.
Read more about the study on the Tufts University website.